Adverum Biotechnologies, Inc. (ADVM)
NASDAQ: ADVM · Real-Time Price · USD
2.710
-0.100 (-3.56%)
At close: May 12, 2025, 4:00 PM
2.760
+0.050 (1.85%)
After-hours: May 12, 2025, 7:48 PM EDT
Adverum Biotechnologies Stock Forecast
ADVM's stock price has decreased by -70.86% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Adverum Biotechnologies stock have an average target of 26.6, with a low estimate of 5.00 and a high estimate of 40. The average target predicts an increase of 881.55% from the current stock price of 2.71.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Adverum Biotechnologies stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $40 → $33 | Strong Buy | Maintains | $40 → $33 | +1,117.71% | Apr 17, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $10 → $5 | Hold | Maintains | $10 → $5 | +84.50% | Apr 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +1,007.01% | Apr 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +1,007.01% | Nov 19, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $12 → $10 | Hold | Maintains | $12 → $10 | +269.00% | Nov 5, 2024 |
Financial Forecast
Revenue This Year
161.50K
from 1.00M
Decreased by -83.85%
Revenue Next Year
230.27K
from 161.50K
Increased by 42.58%
EPS This Year
-5.05
from -6.62
EPS Next Year
-3.38
from -5.05
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 997,500 | 948,150 | 899,850 | ||
| Avg | 161,497 | 230,265 | 291,383 | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.3% | 487.1% | 290.8% | ||
| Avg | -83.9% | 42.6% | 26.5% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.22 | -0.18 | -2.88 | ||
| Avg | -5.05 | -3.38 | -4.47 | ||
| Low | -6.86 | -6.03 | -5.93 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.